SELECTIVE ACCUMULATION OF SR-89 IN METASTATIC DEPOSITS IN BONE - RADIO-HISTOLOGICAL CORRELATION

被引:29
作者
BENJOSEF, E
LUCAS, DR
VASAN, S
PORTER, AT
机构
[1] Departments of Radiation Oncology, Camden-Clark Memorial Hospital, Parksburg, WV
[2] Departments of Pathology, Wayne State University, Detroit, MI
[3] Department of Radiation Oncology, Camden-Clark Memorial Hospital, Parksburg, WV
关键词
D O I
10.1097/00006231-199506000-00007
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The systemic administration of Sr-89 has proven effective in the palliation of painful osseous metastases. Biodistribution studies with the gamma-emitter Sr-85 suggest that both its uptake and retention are increased in bone metastases, where increased mineral turnover takes place. To study the pattern and nature of this process further, bones containing metastatic deposits were obtained from three patients who had previously been treated with 148 MBq of Sr-89. The bones were cut into 0.5-1.0 cm sections. The cut surfaces which faced together were marked with India ink, and adjacent sections were submitted for histology and autoradiography. Stronitium deposition and retention were observed in regions which exhibited significant osteoblastic activity, mostly in areas adjacent to metastatic deposits, but also in subchondral and endosteal locations, as well as in an area corresponding to a pathological fracture with callus formation. With these exceptions, strontium deposition was not observed in histologically normal bone or within the marrow. Our findings demonstrate directly the selective nature of accumulation and retention of Sr-89 and confirm previous clinical impressions.
引用
收藏
页码:457 / 463
页数:7
相关论文
共 20 条
[1]  
Laing A.H., Ackery D.M., Bayly R.J., Et al., Strontium-89 chloride for pain palliation in prostatic skeletal malignancy, Br J Radiol, 64, pp. 816-822, (1991)
[2]  
Porter A.T., Mc ewan A., Powe J.E., Et al., Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer, Int J Radiat Oncol Biol Phys, 25, pp. 805-813, (1993)
[3]  
Robinson R.G., Spicer J.A., Preston D.F., Wegst A.V., Martin N.L., Treatment of metastatic bone pain with strontium-89, Nucl Med Biol, 14, pp. 219-222, (1987)
[4]  
Bauer G., Ray R.D., Kinetics of strontium metabolism in man, J Bone Joint Surg, 40, pp. 171-186, (1958)
[5]  
Dolphin G.W., Eve I.S., The metabolism of strontium in adult humans, Phys Med Biol, 8, pp. 193-203, (1963)
[6]  
Carr T., An attempt to quantitate the short-term move¬ment of strontium in the human adult, Strontium Metabolism, pp. 139-149, (1967)
[7]  
Knizhnikov V.A., Marei A.N., Strontium metabolism in man, Strontium Metabolism, pp. 71-83, (1967)
[8]  
Ophel I.L., Judd J.M., Skeletal distribution of strontium and calcium and strontium-calcium ratios in several species of fish, Stron¬tium Metabolism, pp. 103-111, (1967)
[9]  
Blake G.M., Zivanovic M.A., Mc ewan A.J., Et al., Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate, Eur J Nucl Med, 12, pp. 447-454, (1986)
[10]  
Blake G.M., Zivanovic M.A., Mc ewan A.J., Et al., 89Sr radionuclide therapy: Dosimetry and haematological toxicity in two patients with metastasizing prostatic carcinoma, Eur J Nucl Med, 13, pp. 41-46, (1987)